← All MEPs

Bas Eickhout

European Parliament · 🇳🇱 Netherlands · former MEP

Term: from 18 July 2019 to 18 June 2026

Participation in roll-call votes

94 % of the 2,399 roll-call votes held during their term: took part in the vote (for, against or abstention)

Participation month by month

0 % 50 % 100 % July 2019 : participation 100 % (1 / 1), presence 100 % (1 / 1) 2019 September 2019 : participation 100 % (5 / 5), presence 100 % (5 / 5) October 2019 : participation 100 % (19 / 19), presence 100 % (19 / 19) November 2019 : participation 94 % (17 / 18), presence 94 % (17 / 18) December 2019 : participation 100 % (6 / 6), presence 100 % (6 / 6) January 2020 : participation 100 % (12 / 12), presence 100 % (12 / 12) 2020 February 2020 : participation 100 % (8 / 8), presence 100 % (8 / 8) May 2020 : participation 100 % (54 / 54), presence 100 % (54 / 54) June 2020 : participation 100 % (12 / 12), presence 100 % (12 / 12) July 2020 : participation 100 % (19 / 19), presence 100 % (19 / 19) September 2020 : participation 100 % (24 / 24), presence 100 % (24 / 24) October 2020 : participation 100 % (37 / 37), presence 100 % (37 / 37) November 2020 : participation 94 % (30 / 32), presence 94 % (30 / 32) December 2020 : participation 100 % (30 / 30), presence 100 % (30 / 30) January 2021 : participation 100 % (23 / 23), presence 100 % (23 / 23) 2021 February 2021 : participation 100 % (21 / 21), presence 100 % (21 / 21) March 2021 : participation 100 % (31 / 31), presence 100 % (31 / 31) April 2021 : participation 100 % (81 / 81), presence 100 % (81 / 81) May 2021 : participation 100 % (26 / 26), presence 100 % (26 / 26) June 2021 : participation 100 % (29 / 29), presence 100 % (29 / 29) July 2021 : participation 100 % (27 / 27), presence 100 % (27 / 27) September 2021 : participation 100 % (19 / 19), presence 100 % (19 / 19) October 2021 : participation 100 % (42 / 42), presence 100 % (42 / 42) November 2021 : participation 70 % (19 / 27), presence 70 % (19 / 27) December 2021 : participation 100 % (29 / 29), presence 100 % (29 / 29) January 2022 : participation 100 % (7 / 7), presence 100 % (7 / 7) 2022 February 2022 : participation 100 % (29 / 29), presence 100 % (29 / 29) March 2022 : participation 100 % (37 / 37), presence 100 % (37 / 37) April 2022 : participation 100 % (22 / 22), presence 100 % (22 / 22) May 2022 : participation 91 % (80 / 88), presence 91 % (80 / 88) June 2022 : participation 85 % (39 / 46), presence 85 % (39 / 46) July 2022 : participation 100 % (31 / 31), presence 100 % (31 / 31) September 2022 : participation 100 % (25 / 25), presence 100 % (25 / 25) October 2022 : participation 100 % (32 / 32), presence 100 % (32 / 32) November 2022 : participation 100 % (38 / 38), presence 100 % (38 / 38) December 2022 : participation 100 % (18 / 18), presence 100 % (18 / 18) January 2023 : participation 100 % (16 / 16), presence 100 % (16 / 16) 2023 February 2023 : participation 100 % (29 / 29), presence 100 % (29 / 29) March 2023 : participation 100 % (29 / 29), presence 100 % (29 / 29) April 2023 : participation 100 % (24 / 24), presence 100 % (24 / 24) May 2023 : participation 100 % (93 / 93), presence 100 % (93 / 93) June 2023 : participation 93 % (37 / 40), presence 93 % (37 / 40) July 2023 : participation 98 % (39 / 40), presence 98 % (39 / 40) September 2023 : participation 100 % (27 / 27), presence 100 % (27 / 27) October 2023 : participation 100 % (40 / 40), presence 100 % (40 / 40) November 2023 : participation 75 % (40 / 53), presence 75 % (40 / 53) December 2023 : participation 0 % (0 / 40), presence 0 % (0 / 40) January 2024 : participation 100 % (49 / 49), presence 100 % (49 / 49) 2024 February 2024 : participation 97 % (61 / 63), presence 97 % (61 / 63) March 2024 : participation 100 % (50 / 50), presence 100 % (50 / 50) April 2024 : participation 98 % (209 / 213), presence 98 % (209 / 213) July 2024 : participation 100 % (1 / 1), presence 100 % (1 / 1) September 2024 : participation 100 % (8 / 8), presence 100 % (8 / 8) October 2024 : participation 100 % (13 / 13), presence 100 % (13 / 13) November 2024 : participation 78 % (21 / 27), presence 78 % (21 / 27) December 2024 : participation 100 % (18 / 18), presence 100 % (18 / 18) January 2025 : participation 100 % (6 / 6), presence 100 % (6 / 6) 2025 February 2025 : participation 100 % (10 / 10), presence 100 % (10 / 10) March 2025 : participation 100 % (14 / 14), presence 100 % (14 / 14) April 2025 : participation 91 % (20 / 22), presence 91 % (20 / 22) May 2025 : participation 100 % (54 / 54), presence 100 % (54 / 54) June 2025 : participation 100 % (22 / 22), presence 100 % (22 / 22) July 2025 : participation 100 % (32 / 32), presence 100 % (32 / 32) September 2025 : participation 97 % (28 / 29), presence 97 % (28 / 29) October 2025 : participation 89 % (40 / 45), presence 89 % (40 / 45) November 2025 : participation 100 % (51 / 51), presence 100 % (51 / 51) December 2025 : participation 100 % (31 / 31), presence 100 % (31 / 31) January 2026 : participation 95 % (21 / 22), presence 95 % (21 / 22) 2026 February 2026 : participation 100 % (28 / 28), presence 100 % (28 / 28) March 2026 : participation 98 % (43 / 44), presence 98 % (43 / 44) April 2026 : participation 94 % (48 / 51), presence 94 % (48 / 51) May 2026 : participation 60 % (15 / 25), presence 60 % (15 / 25) June 2026 : participation 0 % (0 / 35), presence 0 % (0 / 35)

Their votes

2,399 votes

DateTextResultTheir vote
The deteriorating situation of human rights in Algeria, in particular the case of journalist Khaled Drareni For
Situation of Fundamental Rights in the European Union - Annual Report for the years 2018-2019 For
Stocktaking of European elections For
The draft Commission implementing regulation approving carbendazim as an existing active substance for use in biocidal products of product-types 7 and 10 For
Commission Implementing Regulation (EU) 2020/1511 of 16 October 2020 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances amidosulfuron, bifenox, chlorotoluron, clofentezine, clomazone, cypermethrin, daminozide, deltamethrin, dicamba, difenoconazole, diflufenican, fenoxaprop-P, fenpropidin, fludioxonil, flufenacet, fosthiazate… For
Lead in gunshot in or around wetlands Against
Application of Union tariff rate quotas and other import quotas For
Improving development effectiveness and efficiency of aid Against
Foreign policy consequences of the COVID-19 outbreak For
A New Industrial Strategy for Europe For
Strengthening Media Freedom: the Protection of Journalists in Europe, Hate Speech, Disinformation and the Role of Platforms For
Addressing product safety in the Single Market For
Towards a more sustainable single market for business and consumers For
Markets in financial instruments Against
Lead in gunshot in or around wetlands Against
The impact of COVID-19 measures on democracy, the rule of law and fundamental rights For
InvestEU Programme Against
Sustainable Europe Investment Plan - How to finance the Green Deal For
Programme for the Union's action in the field of health for the period 2021-2027 (“EU4Health Programme”) For
EU/Seychelles Sustainable Fisheries Partnership Agreement and Implementing Protocol (2020-2026) For
2021 general budget: all sections For
The draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified maize MON 87427 × MON 87460 × MON 89034 × MIR162 × NK603 and genetically modified maize combining two, three or four of the single events MON 87427, MON 87460, MON 89034, MIR162 and NK603, pursuant to Regulation (EC) No 1829/2003 of the… For
The draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified soybean SYHT0H2 (SYN-ØØØH2-5), pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council For
The draft Commission implementing decision authorising the placing on the market of products containing, consisting of or produced from genetically modified maize MON 87427 × MON 89034 × MIR162 × NK603 and genetically modified maize combining two or three of the single events MON 87427, MON 89034, MIR162 and NK603, and repealing Commission Implementing Decision (EU) 2018/1111 pursuant to… For
Common agricultural policy (CAP) 2021–2027 Against
Common agricultural policy (CAP): financing, management and monitoring 2021–2027 Against
Support for strategic plans to be drawn up by Member States under the common agricultural policy (CAP strategic plans) and financed by the European Agricultural Guarantee Fund (EAGF) and by the European Agricultural Fund for Rural Development (EAFRD) 2021–2027 Against
Gender Equality in EU’s foreign and security policy For
An EU legal framework to halt and reverse EU-driven global deforestation For
Employment and social policies of the euro area 2020 For
Economic policies of the euro area 2020 Against
Recommendation to the High Representative and to the Council under Rule 118 in preparation of the 2020 Non-Proliferation of Nuclear Weapons Treaty (NPT) review process, nuclear arms control and nuclear disarmament options For
Proposal for a Recommendation to the Council, the Commission and the Vice-President of the Commission/High Representative of the Union for Foreign Affairs and Security Policy on relations with Belarus For
Intellectual property rights for the development of artificial intelligence technologies For
Civil liability regime for artificial intelligence For
Framework of ethical aspects of artificial intelligence, robotics and related technologies For
Digital Services Act and fundamental rights issues posed Abstention
Digital Services Act: adapting commercial and civil law rules for commercial entities operating online For
Annual implementing report on the EU association agreement with Moldova For
Recommendation to the Council and the Vice-President of the Commission / High Representative of the Union for Foreign Affairs and Security Policy concerning the Implementation and governance of Permanent Structured Cooperation (PESCO) Abstention

Rows per page: 20 40 100 200 All